Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 2,640.5% in the 3rd quarter, Holdings Channel reports. The firm owned 54,399 shares of the company’s stock after purchasing an additional 52,414 shares during the period. BNP Paribas Financial Markets’ holdings in Lifecore Biomedical were worth $268,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Marshall Wace LLP raised its position in shares of Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after buying an additional 139,887 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Lifecore Biomedical during the 2nd quarter valued at about $327,000. Wittenberg Investment Management Inc. raised its holdings in Lifecore Biomedical by 287.8% in the 3rd quarter. Wittenberg Investment Management Inc. now owns 57,896 shares of the company’s stock valued at $285,000 after acquiring an additional 42,967 shares during the last quarter. Rhumbline Advisers lifted its stake in Lifecore Biomedical by 1,668.5% in the 2nd quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after purchasing an additional 25,378 shares in the last quarter. Finally, Legion Partners Asset Management LLC boosted its holdings in shares of Lifecore Biomedical by 0.6% during the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock worth $15,228,000 after purchasing an additional 18,182 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

Insiders Place Their Bets

In other Lifecore Biomedical news, major shareholder Wynnefield Partners Small Cap acquired 122,930 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was purchased at an average price of $4.10 per share, for a total transaction of $504,013.00. Following the completion of the acquisition, the insider now owns 2,095,783 shares of the company’s stock, valued at approximately $8,592,710.30. This trade represents a 6.23 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.21% of the stock is owned by insiders.

Lifecore Biomedical Trading Up 0.4 %

LFCR opened at $7.61 on Monday. The stock has a market capitalization of $280.25 million, a PE ratio of 95.13 and a beta of 0.99. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $8.90. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. The business’s 50 day moving average price is $6.31 and its 200 day moving average price is $5.61.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Friday, October 4th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.07). The business had revenue of $24.71 million for the quarter, compared to analysts’ expectations of $23.30 million. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. As a group, equities research analysts expect that Lifecore Biomedical, Inc. will post -0.99 EPS for the current year.

Analysts Set New Price Targets

LFCR has been the subject of a number of recent research reports. Craig Hallum raised their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 22nd. Barrington Research cut shares of Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 28th.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.